Cervical Cancer Screening Methods among Women Living with Human Immunodeficiency Virus: A Systematic Review and Meta-analysis
- PMID: 41045534
- DOI: 10.4103/ijph.ijph_314_24
Cervical Cancer Screening Methods among Women Living with Human Immunodeficiency Virus: A Systematic Review and Meta-analysis
Abstract
Background: The efficacy of antiretroviral therapy diminishes without addressing comorbidities, particularly the heightened incidence and mortality of cervical cancer among women with human immunodeficiency virus (HIV).
Objectives: This systematic review and meta-analysis aimed to evaluate different cervical cancer screening methods for women living with HIV, given the scarcity of evidence.
Materials and methods: Systematic searches of electronic databases yielded relevant original research published before August 2019, with additional studies identified through cross-referencing.
Results: In a pooled analysis, visual inspection with Lugol's iodine (VILI) demonstrated superior sensitivity, specificity, and accuracy (0.89, 0.88, and 0.88, respectively) compared to cytology testing (0.67, 0.79, and 0.77). VILI outperformed visual inspection with acetic acid (VIA) by 22% in sensitivity and 11% in specificity. Cytology lagged behind VILI by 22% in sensitivity and 9% in specificity. Human papillomavirus (HPV) DNA testing showed a 3% lower sensitivity and 2% lower specificity than VILI. Sequential VIA and cytology testing exhibited lower sensitivity for cervical intraepithelial neoplasia (CIN) 2 + detection than VILI and HPV testing, resulting in more missed cases. HPV testing, in combination with other modalities (VIA, VILI, and cytology), maximized the possibility of CIN2 + detection.
Conclusion: VILI as a standalone test meets criteria for good sensitivity, specificity, and accuracy. The choice of screening modality should consider factors such as cost, geographical location, population type, professional training, and laboratory capacity.
Keywords: Cervical cancer; human immunodeficiency virus; human papillomavirus; screening.
Copyright © 2025 Indian Journal of Public Health.
References
R EFERENCES
-
- Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah AS, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health 2021;9:e161–9.
-
- Akinwuntan AL, Adesina OA, Okolo CA, Oluwasola OA, Oladokun A, Ifemeje AA, et al. Correlation of cervical cytology and visual inspection with acetic acid in HIV-positive women. J Obstet Gynaecol 2008;28:638–41.
-
- Ezechi OC, Odberg Petterson K, Gbajabiamila TA, Idigbe IE, Gab-Okafor CV, Okolo CA, et al. Evaluation of direct visual inspection of the cervix in detecting cytology diagnosed squamous intraepithelial lesion in women of known HIV status. A Randomized Trial (CANHIV Study). Afr J Reprod Health 2016;20:77–88.
-
- Muñoz N, Bosch FX, de Sanjosé S, Tafur L, Izarzugaza I, Gili M, et al. The causal link between human papillomavirus and invasive cervical cancer:A population-based case-control study in Colombia and Spain. Int J Cancer 1992;52:743–9.
-
- Yabroff KR, Lawrence WF, King JC, Mangan P, Washington KS, Yi B, et al. Geographic disparities in cervical cancer mortality:What are the roles of risk factor prevalence, screening, and use of recommended treatment?. J Rural Health 2005;21:149–57.